Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis
The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Clinicians and patients need updated evidence on the comparative effectiveness and safety of diabetes medications to make informed treatment choices. PURPOSE: To evaluate the comparative effectiveness and safety of monotherapy (thiazolidinediones, metformin, sulfonylureas, dipeptidyl peptidase-4 [DPP-4] inhibitors, sodium-glucose cotransporter 2 [SGLT-2] inhibitors, and glucagon-like peptide-1 [GLP-1] receptor agonists) and selected metformin-based combinations in adults with type 2 diabetes. DATA SOURCES: English-language studies from MEDLINE, EMBASE, and the Cochrane Central Register of Controlled Trials, indexed from inception through March 2015 (MEDLINE search updated through December 2015). STUDY SELECTION: Paired reviewers independently identified 179 trials and 25 observational studies of head-to-head monotherapy or metformin-based combinations. DATA EXTRACTION: Two reviewers independently assessed study quality and serially extracted data and graded the strength of evidence. DATA SYNTHESIS: Cardiovascular mortality was lower for metformin versus sulfonylureas; the evidence on all-cause mortality, cardiovascular morbidity, and microvascular complications was insufficient or of low strength. Reductions in hemoglobin A1c values were similar across monotherapies and metformin-based combinations, except that DPP-4 inhibitors had smaller effects. Body weight was reduced or maintained with metformin, DPP-4 inhibitors, GLP-1 receptor agonists, and SGLT-2 inhibitors and increased with sulfonylureas, thiazolidinediones, and insulin (between-group differences up to 5 kg). Hypoglycemia was more frequent with sulfonylureas. Gastrointestinal adverse events were highest with metformin and GLP-1 receptor agonists. Genital mycotic infections were increased with SGLT-2 inhibitors. LIMITATION: Most studies were short, with limited ability to assess rare safety and long-term clinical outcomes. CONCLUSION: The evidence supports metformin as first-line therapy for type 2 diabetes, given its relative safety and beneficial effects on hemoglobin A1c, weight, and cardiovascular mortality (compared with sulfonylureas). On the basis of less evidence, results for add-on therapies to metformin were similar to those for monotherapies. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compounds that modulate NF-κB signalling, including metformin137,235–237, apigenin238, kaempferol238 and BAY 11–7082 (REF.118), have also been shown to decrease SASP production.”
From Cellular senescence in ageing: from mechanisms to therapeutic opportunities (2021) · cites this paper as [236]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
In the citing paper
“Compared with sulfonylureas, metformin as first-line therapy has beneficial effects on A1C, is weight neutral, does not cause hypoglycemia, and reduces cardiovascular mortality (96).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [96]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139 · cited 1×
“We evaluated the heterogeneity among the trials by using the I(2) statistic (11).”
MethodMeta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We generated summary treatment effects with the random-effects model estimated by using the DerSimonian and Laird method in settings of low heterogeneity (I(2) < 50%) (12) and the profile likelihood estimate in settings of high heterogeneity (I(2) ≥ 50%) (13).”
MethodAssessing the quality of reports of randomized clinical trials: Is blinding necessary?
Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J. M., Gavaghan, D. J., & McQuay, H. J. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(95)00134-4 · Cited by 17,582 · cited 1×
“Two independent reviewers assessed risk of bias in individual RCTs by using the criteria of Jadad and colleagues (9), as in our prior review (6).”
MethodDowns, S. H., & Black, N. (1998) · Journal of Epidemiology and Community Health · doi:10.1136/jech.52.6.377 · Cited by 8,252 · cited 1×
“We used the Downs and Black tool for assessment of the risk of bias for the nonrandomized trials and observational studies (10).”
MethodEffects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“diet) on the relative benefits of metformin and sulfonylureas for the spectrum of long-term outcomes important in diabetes (32).”
BackgroundIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Glucose control and vascular complications in veterans with type 2 diabetes
Duckworth, W., Abraira, C., Moritz, T., Reda, D., Emanuele, N., Reaven, P. D., Zieve, F. J., Marks, J., Davis, S. N., Hayward, R., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808431 · Cited by 4,762
Research works printed but not linked: 1
- Wang CP, 2014, J Endocrinol Diabetes Obes, 2
Cited by
Items 101–200 of 733
Bao, T.-Q., Li, Y., Qu, C., Zheng, Z., Yang, H. Q., & Li, P. (2020) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x20500664 · Cited by 62
Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?
Ahmad, E., Sargeant, J. A., Zaccardi, F., Khunti, K., Webb, D. R., & Davies, M. J. (2020) · Pharmaceuticals · doi:10.3390/ph13120427 · Cited by 59
“Given its beneficial effects on HbA1c, weight and cardiovascular mortality and relative safety profile compared to most of the other GLTs, it is reasonable to support metformin as first-line therapy for individuals with new diagnosis of uncomplicated T2D [53]”
BackgroundRecommendations for Practical Use of Metformin, a Central Pharmacological Therapy in Type 2 Diabetes
Vieira, I. H., Barros, L. M., Baptista, C. F., Rodrigues, D. M., & Paiva, I. (2021) · Clinical Diabetes · doi:10.2337/cd21-0043 · Cited by 63
Lee, G., Oh, S.-W., Hwang, S.-S., Yoon, J. W., Kang, S., Joh, H.-K., Kwon, H., Kim, J., & Park, D. (2017) · PLOS ONE · doi:10.1371/journal.pone.0177646 · Cited by 53
Drug Interactions of Metformin Involving Drug Transporter Proteins
Maideen, N. M. P., Jumale, A. H., & Balasubramaniam, R. (2017) · Advanced Pharmaceutical Bulletin · doi:10.15171/apb.2017.062 · Cited by 60
Hasan, T., Mahbub, S., Kumar, D., Gatasheh, M. K., Joy, M. T. R., Goni, M. A., Rana, S., & Hoque, M. A. (2022) · Molecular Physics · doi:10.1080/00268976.2022.2121776 · Cited by 54
Overview of Metformin and Neurodegeneration: A Comprehensive Review
Kruczkowska, W., Gałęziewska, J., Buczek, P., Płuciennik, E., Kciuk, M., & Śliwińska, A. (2025) · Pharmaceuticals · doi:10.3390/ph18040486 · Cited by 58
Should Side Effects Influence the Selection of Antidiabetic Therapies in Type 2 Diabetes?
Grunberger, G. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0853-8 · Cited by 54
Metformin inhibits pro‐inflammatory responses via targeting nuclear factor‐κB in HaCaT cells
Ba, W., Xu, Y., Yin, G., Yang, J., Wang, R., Chi, S.-M., Wang, Y., & Li, C. (2018) · Cell Biochemistry and Function · doi:10.1002/cbf.3367 · Cited by 52
“Metformin, the most widely prescribed oral antidiabetic agent, has been used for nearly a century.(29) Recently, emerging studies on preclinical and clinical trials have shown that metformin exhibits therapy effects on chronic inflammation through improving metabolic parameters such as hyperglycemia, insulin resistanc…”
BackgroundPhytochemicals as Potential Epidrugs in Type 2 Diabetes Mellitus
Ramírez‐Alarcón, K., Victoriano, M., Mardones, L., Villagrán, M., Al‐Harrasi, A., Al-Rawahi, A. N., Martins, N. A., Sharifi‐Rad, J., & Martorell, M. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.656978 · Cited by 53
Preparation and characterization of methylene bisacrylamide crosslinked pectin/acrylamide hydrogels
Siddiqua, A., Ranjha, N. M., Rehman, S., Shoukat, H., Ramzan, N., & Sultana, H. (2021) · Polymer Bulletin · doi:10.1007/s00289-021-03870-z · Cited by 51
Nyandwi, J. B., Ko, G. H., Jin, H., Yun, S. P., Park, S. W., & Kim, H. J. (2021) · Biomolecules · doi:10.3390/biom11101470 · Cited by 50
“In addition, metformin is the first-line medication for the treatment of type 2 diabetes, particularly in people who are overweight [31,32].”
BackgroundPreventive care recommendations to promote health equity
Persaud, N., Sabir, A., Woods, H., Sayani, A., Agarwal, A., Chowdhury, M., de Leon-Demare, K., Ibezi, S., Jan, S. H., Katz, A., et al. (2023) · Canadian Medical Association Journal · doi:10.1503/cmaj.230237 · Cited by 56
Ma, C., Zhang, W., Yang, X., Liu, Y., Liu, L., Feng, K., Zhang, X., Yang, S., Sun, L., Yu, M., et al. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14156 · Cited by 48
“Metformin is a first-line treatment for Type 2 diabetes (Maruthur et al., 2016).”
BackgroundCombination Therapy of Oral Hypoglycemic Agents in Patients with Type 2 Diabetes Mellitus
Moon, M. K., Hur, K. Y., Ko, S., Park, S.-O., Lee, B., Kim, J. H., Rhee, S. Y., Kim, H. J., Choi, K. M., & Kim, N. H. (2017) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2017.41.5.357 · Cited by 54
“In addition, SGLT2i was associated with a lower risk of hypoglycemia and less body weight gain [6,8,13].”
BackgroundMethodInfluentialThioredoxin-Interacting Protein in Cancer and Diabetes
Masutani, H. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0038 · Cited by 53
A new insight into the treatment of diabetes by means of pan PPAR agonists
Chandra, A., Kaur, P., Sahu, S. K., & Mittal, A. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14020 · Cited by 50
Wang, W., Zhou, X., Kwong, J. S., Li, L., Li, Y., & Sun, X. (2017) · Scientific Reports · doi:10.1038/s41598-017-01965-0 · Cited by 48
Masoudi-Sobhanzadeh, Y., Omidi, Y., Amanlou, M., & Masoudi-Nejad, A. (2019) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2019.05.006 · Cited by 47
Li, X., Si, H., Chen, Y., Li, S., Yin, N., & Wang, Z. (2020) · PLoS ONE · doi:10.1371/journal.pone.0243989 · Cited by 52
A Compendium of Perspectives on Diabetes: A Challenge for Sustainable Health in the Modern Era
Verma, A. K., Goyal, Y., Bhatt, D., Dev, K., Alsahli, M. A., Rahmani, A. H., & Almatroudi, A. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s304751 · Cited by 54
Prada-Ramallal, G., Roque, F., Herdeiro, M. T., Takkouche, B., & Figueiras, A. (2018) · BMC Medical Research Methodology · doi:10.1186/s12874-018-0561-3 · Cited by 58
Gomez-Peralta, F., Escalada San Martín, F. J., Menéndez Torre, E., Mata Cases, M., Ferrer García, J. C., Ezkurra Loiola, P., Ávila Lachica, L., Fornos Pérez, J. A., Artola Menéndez, S., Álvarez-Guisasola, F., et al. (2018) · Endocrinología, Diabetes y Nutrición · doi:10.1016/j.endinu.2018.08.004 · Cited by 39
“753 53,0 Sobrepeso (IMC > 28kg/m(2)) y GPA > 108 mg/dL y ≤270 mg/dL 10,7 7,2 % 7,7% 0,7** (5-48) 0.”
Sinclair, A. J., Pennells, D., & Abdelhafiz, A. H. (2022) · Aging Clinical and Experimental Research · doi:10.1007/s40520-022-02142-8 · Cited by 48
“9 from randomised controlled trials (RCT) and observational studies respectively] [68].”
BackgroundMetformin hydrochloride and wound healing: from nanoformulation to pharmacological evaluation
El-Ridy, M. S., Yehia, S. A., Elsayed, I., Younis, M. M., Abdel-Rahman, R. F., & El-Gamil, M. A. (2018) · Journal of Liposome Research · doi:10.1080/08982104.2018.1556291 · Cited by 47
“…as a supplement to diet and exercise, despite its drawbacks of short biological half-life of 1.5–1.6 h and daily requirement of 1.5–3 g/day with an absolute bioavailability of 50–60% when administered orally (Bennett et al. 2011, Inzucchi et al. 2012, Qaseem et al. 2012, Maruthur et al. 2016).”
BackgroundInfluentialWu, B., Chen, M., Gao, Y., Hu, J., Liu, M., Zhang, W., & Huang, W. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.04.009 · Cited by 46
Gao, J., Liu, J., Meng, Z., Li, Y., Hong, Y., Wang, L., He, L., Hu, B. Q., Zheng, Y., Li, T., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.06.015 · Cited by 46
Weight-centric treatment of type 2 diabetes mellitus
Ghusn, W., Hurtado, M. D., & Acosta, A. (2022) · Obesity Pillars · doi:10.1016/j.obpill.2022.100045 · Cited by 40
Triterpenoids from Cyclocarya paliurus that Enhance Glucose Uptake in 3T3-L1 Adipocytes
Fang, Z.-J., Shen, S.-N., Wang, J., Wu, Y., Zhou, C., Mo, J., Lin, L., & Gan, L. (2019) · Molecules · doi:10.3390/molecules24010187 · Cited by 45
“Long-term use of oral hypoglycemic agents or insulin is accompanied by side effects, including hypoglycemic episodes, edema, hepatorenal disturbances, and gastrointestinal problems [1,2].”
BackgroundDey, J. (2017) · Postgraduate Medicine · doi:10.1080/00325481.2017.1307081 · Cited by 47
“increased risk of genital mycotic infections [37,38] and, to a”
BackgroundThe Potential Roles of Artemisinin and Its Derivatives in the Treatment of Type 2 Diabetes Mellitus
Jiang, Y., Shui, J., Zhang, B., Chin, J.-W., & Yue, R. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.585487 · Cited by 48
Metformin is associated with a lower risk of active tuberculosis in patients with type 2 diabetes
Lin, S., Tu, H., Lu, P., Chen, T., Wang, W., Chong, I., & Chen, Y. (2018) · Respirology · doi:10.1111/resp.13338 · Cited by 43
Madsen, K. S., Kähler, P., Kähler, L. K. A., Madsbad, S., Gnesin, F., Metzendorf, M., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012368.pub2 · Cited by 57
Mechanisms of Protective Effects of SGLT2 Inhibitors in Cardiovascular Disease and Renal Dysfunction
Liu, B., Wang, Y., Zhang, Y., & Yan, B. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190828161409 · Cited by 45
Replacing the internal standard to estimate micropollutants using deep and machine learning
Baek, S., Choi, Y., Jeon, J., Pyo, J., Park, J., & Cho, K. H. (2020) · Water Research · doi:10.1016/j.watres.2020.116535 · Cited by 45
Won, D. H., Park, H., Ha, E., Kim, H.-H., Jang, S. W., & Kim, M. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120838 · Cited by 43
Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy
Dannenberg, L., Weske, S., Kelm, M., Levkau, B., & Polzin, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107920 · Cited by 43
Alexander, J. T., Staab, E. M., Wan, W., Franco, M. I., KNITTER, A. C., Skandari, M. R., Bolen, S. D., Maruthur, N. M., Huang, E. S., Philipson, L. H., et al. (2021) · Journal of General Internal Medicine · doi:10.1007/s11606-021-07105-9 · Cited by 46
Self-citationDeol, H., Lekkakou, L., Viswanath, A., & Pappachan, J. M. (2016) · Endocrine · doi:10.1007/s12020-016-1125-0 · Cited by 44
Practical Insights Into Improving Adherence to Metformin Therapy in Patients With Type 2 Diabetes
Christofides, E. A. (2019) · Clinical Diabetes · doi:10.2337/cd18-0063 · Cited by 47
“In addition to being an effective firstline antihyperglycemic therapy for newly diagnosed patients, metformin is well tolerated and inexpensive (7,9), making it ideally suited as a long-term treatment.”
BackgroundShoshan‐Barmatz, V., Anand, U., Crystal, E. N., Carlo, M. D., & Shteinfer‐Kuzmine, A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.730048 · Cited by 44
Oh, S. H., Park, J., Lee, S. J., Kang, S. S., & Mo, J. (2022) · Expert Systems with Applications · doi:10.1016/j.eswa.2022.117932 · Cited by 42
He, M., Lu, B., Opoku, M., Zhang, L., Xie, W., Jin, H., Chen, S., Li, Y., & Deng, Z. (2022) · Cells · doi:10.3390/cells11193012 · Cited by 43
“Along with more in-depth research on metformin in the past decades, its therapeutic effect has also been expanded to other diseases, such as cardiovascular disease [4,5], liver disease [6,7], obesity [8], polycystic ovary syndrome (PCOS) [9,10], tumor [11], aging [12–15], and osteoporosis [16].”
BackgroundInzucchi, S. E. (2017) · Diabetes Care · doi:10.2337/dc16-2372 · Cited by 50
Vest, L. S., Koraishy, F. M., Zhang, Z., Lam, N. N., Schnitzler, M. A., Dharnidharka, V. R., Axelrod, D., Naik, A. S., Alhamad, T. A., Kasiske, B. L., et al. (2018) · Clinical Transplantation · doi:10.1111/ctr.13302 · Cited by 41
Kaplan, D. E., Serper, M., John, B. V., Tessiatore, K. M., Lerer, R., Mehta, R., Fox, R., Aytaman, A., Baytarian, M., Hunt, K., et al. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.026 · Cited by 41
Anti-Aging Drugs and the Related Signal Pathways
Du, N., Ruigang, Y., Jiang, S., Niu, Z., Zhou, W., Liu, C., Gao, L., & Sun, Q. (2024) · Biomedicines · doi:10.3390/biomedicines12010127 · Cited by 43
Cardioprotective anti-hyperglycaemic medications: a review of clinical trials
Ahmed, H. M., Khraishah, H., & Cho, L. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx668 · Cited by 45
Li, Y., Wang, C., Jin, Y., Chen, H., Cao, M., Li, W., Luo, H., & Wu, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109734 · Cited by 43
Unraveling the Peculiar Features of Mitochondrial Metabolism and Dynamics in Prostate Cancer
Fontana, F., Anselmi, M., & Limonta, P. (2023) · Cancers · doi:10.3390/cancers15041192 · Cited by 41
Metformin and the Liver: Unlocking the Full Therapeutic Potential
Perazza, F., Leoni, L., Colosimo, S., Musio, A., Bocedi, G., D’Avino, M., Agnelli, G., Nicastri, A., Rossetti, C., Sacilotto, F., et al. (2024) · Metabolites · doi:10.3390/metabo14040186 · Cited by 43
“…in 1995 [210] and has long been considered as a fi rst-line therapy by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes [211], as well as by the American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) [212].”
BackgroundKapo, S. M., Kusturica, J., Gušić, E., Rakanović-Todić, M., Šečić, D., Burnazović-Ristić, L., & Kulo, A. (2018) · Acta Medica Academica · doi:10.5644/ama2006-124.196 · Cited by 40
Vasconcelos, I., da Silva, P. H. R., Dias, D. R. D., Marques, M. B. D. F., Mussel, W. D. N., Pedrosa, T. A., Silva, M. E. S. R. E., Freitas, R. F. D. S., de Sousa, R. G., & Fernandes, C. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111191 · Cited by 40
“diseases, because it is safer, since the incidence of hypoglycemia due to GCZ is lower [9,12].”
BackgroundMetformin: A promising drug for human cancers (Review)
Wu, H., Huang, D., Zhou, H., Sima, X., Wu, Z., Sun, Y., Wang, L., Ruan, Y., Wu, Q., Wu, F., et al. (2022) · Oncology Letters · doi:10.3892/ol.2022.13325 · Cited by 42
Self-citationGDF-15 as a Weight Watcher for Diabetic and Non-Diabetic People Treated With Metformin
Ouyang, J., Isnard, S., Lin, J., Fombuena, B., Peng, X., Chen, Y., & Routy, J.-P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.581839 · Cited by 39
“showed that metformin decreased body weight more than dipeptidyl peptidase-4 (DPP-4) inhibitors which were expected to decrease body weight (18).”
BackgroundInsight into continuous glucose monitoring: from medical basics to commercialized devices
Chmayssem, A., Nadolska, M., Tubbs, E., Sadowska, K., Vadgma, P., Shitanda, I., Tsujimura, S., Lattach, Y., Peacock, M., Tingry, S., et al. (2023) · Microchimica Acta · doi:10.1007/s00604-023-05743-w · Cited by 40
Pharmacologic Glycemic Management of Type 2 Diabetes in Adults---2024 Update
Shah, B. R., BAJAJ, H. S., Butalia, S., Dasgupta, K., Eurich, D. T., Jain, R., Leung, K., Mansell, K. D., & Simpson, S. H. (2024) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2024.08.002 · Cited by 41
Wei, Z., Wei, Y., Li, H., Shi, D., Yang, D., Yin, J., Zhou, S., Chen, T., Lǐ, J., & Jin, M. (2022) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2022.128474 · Cited by 41
Action Mechanism of Metformin and Its Application in Hematological Malignancy Treatments: A Review
Zhang, Y., Zhou, F., Guan, J., Zhou, L., & Chen, B. (2023) · Biomolecules · doi:10.3390/biom13020250 · Cited by 41
Pharmacotherapy of ‘treatment resistant’ type 2 diabetes
Scheen, A. J. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1297424 · Cited by 40
Newby, D., Linden, A. B., Fernandes, M., Winchester, L. M., Molero, Y., Sproviero, W., Ghose, U., Li, Q. S., Launer, L. J., van Duijn, C. M., et al. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003036 · Cited by 37
Metformin Alleviates the Bone Loss Induced by Ketogenic Diet: An In Vivo Study in Mice
Liu, Q., Xu, X., Zhou, Y., Liu, Y., Wu, X., Huang, Z., Liu, J., Huang, Z., Kong, G., Ding, J., et al. (2018) · Calcified Tissue International · doi:10.1007/s00223-018-0468-3 · Cited by 37
Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin
Feng, S.-W., Chang, P.-C., Chen, H., Hueng, D., Li, Y., & Huang, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158171 · Cited by 38
Current type 2 diabetes guidelines: Individualized treatment and how to make the most of metformin
Chan, J. C. N., Yang, A., Chu, N. H. S., & Chow, E. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15700 · Cited by 38
SGLT2 inhibitors, an Accomplished Development in Field of Medicinal Chemistry: an Extensive Review
Manoj, A., Das, S., Ramachandran, A. K., Alex, A. T., & Joseph, A. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0154 · Cited by 39
Hall, J. J., Eurich, D. T., Nagy, D. K., Tjosvold, L., & Gamble, J. (2020) · Journal of General Internal Medicine · doi:10.1007/s11606-020-05731-3 · Cited by 35
Khunti, K., Hassanein, M. M., Lee, M., Mohan, V., & Amod, A. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00833-x · Cited by 38
Silverii, G. A. (2024) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.15749 · Cited by 33
Managing metabolic diseases: The roles and therapeutic prospects of herb-derived polysaccharides
Xu, X., Wang, L., Zhang, K., Zhang, Y., & Fan, G. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114538 · Cited by 34
Harrington, J. L., de Albuquerque Rocha, N., Patel, K. V., Verma, S., & McGuire, D. K. (2018) · Current Diabetes Reports · doi:10.1007/s11892-018-1035-z · Cited by 32
Gluc-HET, a complementary chick embryo model for the characterization of antidiabetic compounds
Haselgrübler, R., Stübl, F., Essl, K., Iken, M., Schröder, K. R., & Weghuber, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0182788 · Cited by 32
Packer, M. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0648-x · Cited by 32
The use of South African botanical species for the control of blood sugar
Cock, I. E., Ndlovu, N. A., & van Vuuren, S. F. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.113234 · Cited by 35
Chepulis, L. M., Mayo, C., Morison, B. J., Keenan, R., Lao, C., Paul, R. G., & Lawrenson, R. A. (2020) · Journal of Primary Health Care · doi:10.1071/hc20043 · Cited by 32
Effective data-driven precision medicine by cluster-applied deep reinforcement learning
Oh, S. H., Lee, S. J., & Park, J. (2022) · Knowledge-Based Systems · doi:10.1016/j.knosys.2022.109877 · Cited by 38
Anwardeen, N. R., Naja, K., & Elrayess, M. A. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1506767 · Cited by 33
Akimoto, H., Tezuka, K., Nishida, Y., Nakayama, T., Takahashi, Y., & Asai, S. (2019) · Pharmacology Research & Perspectives · doi:10.1002/prp2.536 · Cited by 32
Meng, X., Tang, G., Zhao, C., Liu, Q., Xu, X., & Cao, S. (2020) · World Journal of Gastroenterology · doi:10.3748/wjg.v26.i24.3432 · Cited by 31
Ghanemi, A., Melouane, A., Yoshioka, M., & St‐Amand, J. (2020) · Genes · doi:10.3390/genes11080875 · Cited by 33
Singh, A. K., Singh, R., & Chakraborty, P. P. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s295459 · Cited by 33
Sani, M. A., Yaghmaei, P., Hajebrahimi, Z., & Roodbari, N. H. (2022) · Journal of Obesity · doi:10.1155/2022/1015669 · Cited by 32
“Also, it increases the response of the body to insulin [51].”
BackgroundThe Ketogenic Effect of SGLT-2 Inhibitors—Beneficial or Harmful?
Koutentakis, M., Kuciński, J., Świeczkowski, D., Surma, S., Filipiak, K. J., & Gąsecka, A. (2023) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd10110465 · Cited by 38
Comparative Effectiveness for Glycemic Control in Older Adults with Diabetes
Quartuccio, M., Buta, B. J., & Kalyani, R. R. (2017) · Current Geriatrics Reports · doi:10.1007/s13670-017-0215-z · Cited by 32
Impact of diabetes mellitus on epithelial ovarian cancer survival
Akhavan, S., Ghahghaei‐Nezamabadi, A., Modares-Gilani, M., Mousavi, A. S., Sepidarkish, M., Tehranian, A., & Rezayof, E. (2018) · BMC Cancer · doi:10.1186/s12885-018-5162-3 · Cited by 31
“Interestingly, metformin, the first line medication for the treatment of type 2 diabetes, particularly in overweight patients [18, 19] have positive impact on survival in diabetes ovarian cancer patients [4, 20–23].”
Luo, C., Wang, X., Huang, H., Mao, X., Zhou, H., & Liu, Z. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00371 · Cited by 31
ATP-Sensitive Potassium Channels in Migraine: Translational Findings and Therapeutic Potential
Clement, A., Guo, S., Jansen‐Olesen, I., & Christensen, S. L. (2022) · Cells · doi:10.3390/cells11152406 · Cited by 30
“Sulfonylureas are used clinically to promote insulin secretion in type 2 diabetes [125].”
BackgroundClinical applications of small molecule inhibitors of Pregnane X receptor
Staudinger, J. L. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.02.002 · Cited by 31
Metformin ameliorates acetaminophen-induced sub-acute toxicity via antioxidant property
Tripathi, S. S., Singh, S., Garg, G., Kumar, R., Verma, A. K., Singh, A. K., Bissoyi, A., & Rizvi, S. I. (2019) · Drug and Chemical Toxicology · doi:10.1080/01480545.2019.1658769 · Cited by 34
“It has been ascribed for several biological benefits in addition to its role in improving insulin sensitivity by lowering blood glucose (Malek et al. 2013, Maruthur et al. 2016).”
BackgroundXing-yuan, M., Cui, Z., Du, Z., & Lin, H. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29605 · Cited by 31
The Effectiveness of Metformin in Diabetes Prevention: A Systematic Review and Meta-Analysis
Patel, D., Ayesha, I. E., Monson, N. R., Klair, N., Patel, U., Saxena, A., & Hamid, P. (2023) · Cureus · doi:10.7759/cureus.46108 · Cited by 29
“Maruthur et al. conducted a systematic review and meta-analysis, which showed that metformin, was effective in reducing the incidence of diabetes in individuals with IGT, MetS, and polycystic ovary syndrome [33].”
BackgroundType 2 diabetes mellitus management in patients with chronic kidney disease: an update
Kleinaki, Z., Kapnisi, S., Theodorelou‐Charitou, S., Nikas, I. P., & Paschou, S. Α. (2020) · HORMONES · doi:10.1007/s42000-020-00212-y · Cited by 32
Yen, H., Chang, Y.-T., Yee, F.-J., & Huang, Y. (2020) · American Journal of Clinical Dermatology · doi:10.1007/s40257-020-00565-5 · Cited by 30
Kadam, U. T., Roberts, I., White, S. J., Bednall, R., Khunti, K., Nilsson, P. M., & Lawson, C. A. (2018) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2018.10.014 · Cited by 33
Cervantes-Arista, C., Román‐Guerrero, A., Oidor-Chan, V. H., de León‐Sánchez, F. D., Lorena, Á.-R. E., Pelayo‐Zaldívar, C., Sierra-Palacios, E. D. C., & Mendoza‐Espinoza, J. A. (2020) · Food Chemistry · doi:10.1016/j.foodchem.2020.127076 · Cited by 29
Ismail‐Beigi, F., Moghissi, E. S., Kosiborod, M., & Inzucchi, S. E. (2017) · Journal of General Internal Medicine · doi:10.1007/s11606-017-4061-7 · Cited by 28
Advances in the study of RNA-binding proteins in diabetic complications
Chen, X., Wu, J., Li, Z., Han, J., Xia, P., Shen, Y., Ma, J., Liu, X., Zhang, J., & Yu, P. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101515 · Cited by 28
Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy
Gales, L. N., Forsea, L., Mitrea, D., Stefanica, I., Stanculescu, I., Mitrica, R. I., Géorgescu, M., Trifanescu, O. G., Anghel, R. M., & Serbanescu, L. G. (2022) · Medicina · doi:10.3390/medicina58091239 · Cited by 30
“Metformin, a biguanide antihyperglycemic agent, is the most widely used first-line treatment for type 2 diabetes [2].”
BackgroundKim, J., Park, S., Kim, H., & Je, N. K. (2019) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-019-02751-9 · Cited by 27
Cardiovascular Disease Prevention and Therapy in Women With Type 2 Diabetes
Cocchi, C., Coppi, F., Farinetti, A., & Mattioli, A. V. (2021) · Future Cardiology · doi:10.2217/fca-2021-0011 · Cited by 27
Diabetes Mellitus and Heart Failure With Preserved Ejection Fraction: Role of Obesity
Dhore-Patil, A., Thannoun, T., Samson, R., & Jemtel, T. H. L. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2021.785879 · Cited by 30
Metadata
- Authors
- Maruthur, N. M., Tseng, E., Hutfless, S., Wilson, L. M., Suarez-Cuervo, C., Berger, Z., Chu, Y., Iyoha, E., Segal, J. B., & Bolen, S.
- Affiliations
- MetroHealth (US)
- From The Johns Hopkins University School of Medicine; The Johns Hopkins University Bloomberg School of Public Health; and Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, Maryland, and Center for Health Care Research and Policy, MetroHealth/Case Western Reserve University; MetroHealth Medical Center; and Case Western Reserve University, Cleveland, Ohio.
- ORCID
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-06-07
- Volume
- 164
- Issue
- 11
- Pages
- 740-751
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2340898396
- Cited by
- 682
- References
- 66
- Citations by year
- 2026: 37 · 2025: 52 · 2024: 60 · 2023: 68 · 2022: 80 · 2021: 90 · 2020: 89 · 2019: 71 · 2018: 68 · 2017: 56 · 2016: 11
- FWCI
- 10.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Locations
- Annals of Internal Medicine (publishedVersion)
- PubMed (publishedVersion)
- Annals of Internal Medicine
- Funders
- Agency for Healthcare Research and Quality (290-2012-00007-I)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, metformin, monotherapy, thiazolidinediones, sulfonylureas, DPP-4 inhibitors, SGLT2 inhibitors, GLP-1 receptor agonists, cardiovascular mortality, glycemic control, HbA1c, weight loss, hypoglycemia, gastrointestinal adverse effects, genital mycotic infections, first-line therapy
- MeSH terms
- Adult, Cardiovascular Diseases, Cause of Death, Diabetes Mellitus, Type 2, Drug Therapy, Combination, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Metformin, Comparative Effectiveness Research
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.